相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events
Antonella d'Arminio Monforte et al.
AIDS (2013)
Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials
Calvin J. Cohen et al.
AIDS (2013)
Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1-Infected Patients: Pooled Results From the Phase 3 Double-Blind Randomized ECHO and THRIVE Trials
Calvin J. Cohen et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2012)
Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial
G. Faetkenheuer et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care
Heidi M. Crane et al.
AIDS (2011)
Elevated triglycerides and risk of myocardial infarction in HIV-positive persons
Signe W. Worm et al.
AIDS (2011)
Cardiovascular risk factors in patients on long-term treatment with nevirapine- or efavirenz-based regimens
Paolo Maggi et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial
Calvin J. Cohen et al.
LANCET (2011)
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial
Jean-Michel Molina et al.
LANCET (2011)
Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study
Signe Westring Worm et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment
Richard H. Haubrich et al.
AIDS (2009)
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
Jeffrey L. Lennox et al.
LANCET (2009)
Human Immunodeficiency Virus and Highly Active Antiretroviral Therapy-Associated Metabolic Disorders and Risk Factors for Cardiovascular Disease
Erdembileg Anuurad et al.
METABOLIC SYNDROME AND RELATED DISORDERS (2009)
Abacavir-Lamivudine versus Tenofovir-Emtricitabine for Initial HIV-1 Therapy
Paul E. Sax et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The Role of Protease Inhibitors in the Pathogenesis of HIV-Associated Lipodystrophy: Cellular Mechanisms and Clinical Implications
Oliver P. Flint et al.
TOXICOLOGIC PATHOLOGY (2009)
General cardiovascular risk profile for use in primary care - The Framingham Heart Study
Ralph B. D'Agostino et al.
CIRCULATION (2008)
The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy
Jose A. Perez-Molina et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy
D. William Cameron et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Class of antiretroviral drugs and the risk of myocardial infarction
Nina Friis-Moller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV
JE Gallant et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Medical progress - Cardiovascular risk and body-fat abnormalities in HIV-infected adults.
S Grinspoon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1
F van Leth et al.
PLOS MEDICINE (2004)
Cardiovascular disease risk factors in HIV patients -: association with antiretroviral therapy.: Results from the DAD study
N Friis-Moller et al.
AIDS (2003)
Clinical assessment of HIV-associated lipodystrophy in an ambulatory population
KA Lichtenstein et al.
AIDS (2001)
Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy -: A 5-year cohort study
S Tsiodras et al.
ARCHIVES OF INTERNAL MEDICINE (2000)
Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection
SA Mallal et al.
AIDS (2000)
分享论文
